SCP
ZNTL icon

Sivia Capital Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sivia Capital Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97K Hold
20,000
– – 0.01% 534
2026
Q1 		$46.8K Hold
20,000
– – 0.01% 451
2025
Q4 		$27K Buy
+20,000
New +$29.1K 0.01% 553

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Sivia Capital Partners's ZNTL Position: Q2 2026 in Review

Sivia Capital Partners held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 20,000 shares worth $97K. The position accounts for 0.01% of the portfolio, ranked #534.

Sivia Capital Partners first reported a position in ZNTL in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Sivia Capital Partners held 20,000 shares of Zentalis Pharmaceuticals worth $97K as of Q2 2026.
  • Sivia Capital Partners left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up 0.01% of Sivia Capital Partners's portfolio in Q2 2026, its #534 holding.
  • Sivia Capital Partners first reported a position in Zentalis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.